Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer
Authors:
Open Access
- 12 March 2017
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (42) , 71447-71455
Abstract
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Jennifer Podolak1, Kristi Eilers1, Timothy Newby1, Rachel Slottke1, Erin Tucker1, Susan B. Olson2, Hui-wen Lue1, Jack Youngren3, Rahul Aggarwal3, Eric J. Small3, Julie N. Graff1, Joshi J. Alumkal1, Tomasz M. Beer1, George V. Thomas1, 2 1Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA 2Department of Pathology and Laboratory Medicine, Oregon Health and Science University, Portland, OR, USA 3School of Medicine, University of California, San Francisco, San Francisco, CA, USA Correspondence to: George V. Thomas, email: thomasge@ohsu.edu Keywords: prostate cancer, circulating tumor cells, androgen receptor, metastases, metastatic castration resistant prostate cancer Received: September 30, 2016 Accepted: February 27, 2017 Published: March 13, 2017 ABSTRACT Increased AR activity has been shown to be preserved in spatially distinct metastatic tumors from the same patient suggesting the requirement for lineage-specific dependencies for metastatic castration resistant prostate cancer (mCRPC). Amplification of the AR gene is a common mechanism by which mCRPC increase AR activity. To determine whether AR amplification in circulating tumor cells (CTC) could complement metastatic tissue biopsies in men undergoing treatment for mCRPC, we developed a novel two-step assay to isolate CTCs and subsequently analyzed AR amplification status in CTCs and matched biopsy tissue from the same patient by fluorescence in situ hybridization (FISH). AR gene status in CTCs showed strong concordance with AR gene status in matched tissue samples in 24 of 25 patients (Correlation: 96%; Kappa: 0.83; Sensitivity: 100%, Specificity: 83%). Our work demonstrates that AR amplification is conserved between CTCs and biopsies and that CTCs can serve as non-invasive surrogate to document AR amplification in mCRPC.Keywords
This publication has 15 references indexed in Scilit:
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyEuropean Urology, 2017
- Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid BiopsyCancer Discovery, 2016
- Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancerNature Medicine, 2016
- PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patientsBritish Journal of Cancer, 2015
- Utilizing circulating tumor cells: challenges and pitfallsCurrent Opinion in Genetics & Development, 2011
- Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate CancerClinical Cancer Research, 2009
- Mechanisms mediating androgen receptor reactivation after castrationUrologic Oncology: Seminars and Original Investigations, 2009
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate CancerClinical Cancer Research, 2008
- Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling AxisJournal of Clinical Oncology, 2005
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003